JP2020530762A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020530762A5 JP2020530762A5 JP2020501174A JP2020501174A JP2020530762A5 JP 2020530762 A5 JP2020530762 A5 JP 2020530762A5 JP 2020501174 A JP2020501174 A JP 2020501174A JP 2020501174 A JP2020501174 A JP 2020501174A JP 2020530762 A5 JP2020530762 A5 JP 2020530762A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- domain
- variable domain
- antibody
- polypeptide molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023083663A JP2023103451A (ja) | 2017-07-14 | 2023-05-22 | 改善された二重特異性ポリペプチド分子 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762532713P | 2017-07-14 | 2017-07-14 | |
| DE102017115966.5 | 2017-07-14 | ||
| US62/532,713 | 2017-07-14 | ||
| DE102017115966.5A DE102017115966A1 (de) | 2017-07-14 | 2017-07-14 | Polypeptidmolekül mit verbesserter zweifacher Spezifität |
| DE102017119866 | 2017-08-30 | ||
| DE102017119866.0 | 2017-08-30 | ||
| US201862658318P | 2018-04-16 | 2018-04-16 | |
| US62/658,318 | 2018-04-16 | ||
| DE102018108995.3 | 2018-04-16 | ||
| DE102018108995 | 2018-04-16 | ||
| PCT/EP2018/069157 WO2019012141A1 (en) | 2017-07-14 | 2018-07-13 | IMPROVED POLYPEPTIDE MOLECULE WITH DOUBLE SPECIFICITY |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023083663A Division JP2023103451A (ja) | 2017-07-14 | 2023-05-22 | 改善された二重特異性ポリペプチド分子 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020530762A JP2020530762A (ja) | 2020-10-29 |
| JP2020530762A5 true JP2020530762A5 (enExample) | 2021-08-26 |
Family
ID=62951983
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020501174A Pending JP2020530762A (ja) | 2017-07-14 | 2018-07-13 | 改善された二重特異性ポリペプチド分子 |
| JP2018134424A Active JP6784724B2 (ja) | 2017-07-14 | 2018-07-17 | 改善された二重特異性ポリペプチド分子 |
| JP2023083663A Pending JP2023103451A (ja) | 2017-07-14 | 2023-05-22 | 改善された二重特異性ポリペプチド分子 |
| JP2023198791A Pending JP2024023385A (ja) | 2017-07-14 | 2023-11-24 | 改善された二重特異性ポリペプチド分子 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018134424A Active JP6784724B2 (ja) | 2017-07-14 | 2018-07-17 | 改善された二重特異性ポリペプチド分子 |
| JP2023083663A Pending JP2023103451A (ja) | 2017-07-14 | 2023-05-22 | 改善された二重特異性ポリペプチド分子 |
| JP2023198791A Pending JP2024023385A (ja) | 2017-07-14 | 2023-11-24 | 改善された二重特異性ポリペプチド分子 |
Country Status (28)
| Country | Link |
|---|---|
| US (8) | US20190016802A1 (enExample) |
| EP (3) | EP3985029A1 (enExample) |
| JP (4) | JP2020530762A (enExample) |
| KR (2) | KR20200026995A (enExample) |
| CN (2) | CN110914307A (enExample) |
| AU (2) | AU2018298884A1 (enExample) |
| BR (2) | BR112020000762A2 (enExample) |
| CA (2) | CA3069610A1 (enExample) |
| CO (2) | CO2020001029A2 (enExample) |
| CR (2) | CR20200014A (enExample) |
| CY (2) | CY1124091T1 (enExample) |
| DK (2) | DK3428194T3 (enExample) |
| ES (2) | ES2871146T3 (enExample) |
| HR (1) | HRP20211744T1 (enExample) |
| HU (2) | HUE057110T2 (enExample) |
| LT (2) | LT3428194T (enExample) |
| MA (1) | MA46299B1 (enExample) |
| MD (2) | MD3428194T2 (enExample) |
| MX (1) | MX2020011744A (enExample) |
| PE (2) | PE20200615A1 (enExample) |
| PL (2) | PL3652215T3 (enExample) |
| PT (2) | PT3428194T (enExample) |
| RS (2) | RS62544B1 (enExample) |
| SG (2) | SG11202000025SA (enExample) |
| SI (2) | SI3652215T1 (enExample) |
| TW (2) | TWI762677B (enExample) |
| WO (2) | WO2019012141A1 (enExample) |
| ZA (1) | ZA202000842B (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201604458D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
| ES2871146T3 (es) * | 2017-07-14 | 2021-10-28 | Immatics Biotechnologies Gmbh | Molécula de polipéptido con especificidad dual mejorada |
| BR112020023195A2 (pt) | 2018-05-14 | 2021-09-28 | Immunocore Limited | Polipeptídeos de ligação bifuncional, composição farmacêutica, ácido nucleico, vetor de expressão, célula hospedeira, método para preparar o polipeptídeo de ligação bifuncional, e método para tratar um distúrbio autoimune |
| GB201904328D0 (en) | 2019-03-28 | 2019-05-15 | Immunocore Ltd | Specific binding molecules |
| PH12021552979A1 (en) | 2019-05-27 | 2023-10-09 | Immatics Us Inc | Viral vectors and their use in adoptive cellular therapy |
| US20210032370A1 (en) * | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| DE102019121007A1 (de) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
| CN112409474B (zh) * | 2019-08-23 | 2023-02-28 | 香雪生命科学技术（广东）有限公司 | 一种识别ssx2抗原的高亲和力tcr |
| GB201915282D0 (en) | 2019-10-22 | 2019-12-04 | Immunocore Ltd | Specific binding molecules |
| CN114786720B (zh) * | 2019-12-05 | 2025-08-22 | 艾贝乐医药科技有限公司 | TriAx抗体的组合物及其制备和使用方法 |
| MX2022010461A (es) | 2020-02-24 | 2022-12-13 | Immatics Us Inc | Metodos para expandir linfocitos t para el tratamiento de cancer y neoplasias malignas asociadas. |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| GB202006629D0 (en) | 2020-05-05 | 2020-06-17 | Immunocore Ltd | Specific binding molecules |
| GB202010329D0 (en) | 2020-07-06 | 2020-08-19 | Immunocore Ltd | Specific binding molecules |
| US20220056411A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
| WO2022147029A2 (en) | 2020-12-31 | 2022-07-07 | Immatics US, Inc. | Cd8 polypeptides, compositions, and methods of using thereof |
| WO2022184805A1 (en) | 2021-03-03 | 2022-09-09 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding sars-cov-2 antigenic peptides in complex with a major histocompatibility complex protein |
| EP4304725A1 (en) | 2021-03-09 | 2024-01-17 | CDR-Life AG | Rabbit-derived antigen binding protein nucleic acid libraries |
| BR112023022765A2 (pt) | 2021-05-05 | 2024-01-02 | Immatics Biotechnologies Gmbh | Proteínas de ligação ao antígeno que ligam especificamente o prame |
| EP4113120A1 (en) | 2021-06-28 | 2023-01-04 | Immatics Biotechnologies GmbH | Method of characterizing the binding characteristics between a peptide of interest and mhc molecules |
| US20230024554A1 (en) | 2021-06-28 | 2023-01-26 | Immatics Biotechnologies Gmbh | Method of characterizing the binding characteristics between a peptide of interest and mhc molecules |
| EP4377330A1 (en) | 2021-07-27 | 2024-06-05 | Immatics Biotechnologies GmbH | Antigen binding proteins specifically binding ct45 |
| CN117964777A (zh) * | 2021-08-26 | 2024-05-03 | 瑅安生物医药（杭州）有限公司 | 一种接近天然分子的多肽融合分子 |
| WO2023044488A1 (en) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Monocyte depletion of t cells populations for t-cell therapy |
| US20230190805A1 (en) | 2021-10-06 | 2023-06-22 | Immatics Biotechnologies Gmbh | Methods of identifying metastatic lesions in a patient and treating thereof |
| US20230142468A1 (en) | 2021-11-08 | 2023-05-11 | Immatics US, Inc. | Methods for generating cell spheroids |
| EP4448108A1 (en) | 2021-11-08 | 2024-10-23 | Immatics Biotechnologies GmbH | Adoptive cell therapy combination treatment and compositions thereof |
| CA3240046A1 (en) * | 2021-12-14 | 2023-06-22 | Cdr-Life Ag | Dual mhc-targeting t cell engager |
| IL314832A (en) | 2022-02-20 | 2024-10-01 | Immunocore Ltd | Hiv-specific binding molecules and tcr |
| EP4514834A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof |
| JP2025516189A (ja) | 2022-04-28 | 2025-05-27 | イマティクス ユーエス，アイエヌシー． | 膜結合型ｉｌ－１５、ｃｄ８ポリペプチド、細胞、組成物、およびそれらの使用方法 |
| US20240066127A1 (en) | 2022-04-28 | 2024-02-29 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| WO2023209124A1 (en) * | 2022-04-29 | 2023-11-02 | Immatics Biotechnologies Gmbh | Mammalian display platform for multispecific antigen binding proteins |
| EP4519418A1 (en) | 2022-05-05 | 2025-03-12 | Immatics US, Inc. | Methods for improving t cell efficacy |
| WO2023240124A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Pseudotyped viral particles for targeting tcr-expressing cells |
| EP4569324A1 (en) | 2022-08-08 | 2025-06-18 | Immatics Biotechnologies GmbH | Guided positional scanning method |
| KR20250067130A (ko) | 2022-09-14 | 2025-05-14 | 씨디알-라이프 아게 | Mage-a4 펩티드 이중 t 세포 연결체 |
| EP4634216A1 (en) | 2022-12-16 | 2025-10-22 | Repertoire Immune Medicines, Inc. | T cell receptors binding hpv-16 epitopes |
| CN120530140A (zh) | 2023-01-06 | 2025-08-22 | 英美偌科有限公司 | 针对piwil1肽-hla复合物的结合分子 |
| AU2024206754A1 (en) | 2023-01-06 | 2025-07-10 | Immunocore Limited | Binding molecules against a prame peptide-hla complex |
| WO2025008513A1 (en) | 2023-07-05 | 2025-01-09 | Immatics Biotechnologies Gmbh | A method of identifying mhc-binding proteins and interacting peptides in a sample |
| TW202506719A (zh) | 2023-07-27 | 2025-02-16 | 德商艾瑪提克生物技術有限公司 | 針對mageb2之抗原結合蛋白 |
| WO2025085855A2 (en) * | 2023-10-20 | 2025-04-24 | BioNTech SE | Multispecific t cell engagers compositions and methods of use thereof |
| WO2025087436A1 (zh) * | 2023-10-27 | 2025-05-01 | 北京可瑞生物科技有限公司 | 基于t细胞受体的多特异性多肽分子及其组合物和用途 |
| US20250134931A1 (en) | 2023-11-01 | 2025-05-01 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| WO2025094054A1 (en) * | 2023-11-01 | 2025-05-08 | Immunocore Limited | Method for purifying small multi-domain proteins |
| GB202320012D0 (en) * | 2023-12-22 | 2024-02-07 | Immunocore Ltd | Bispecific molecules |
| WO2025233431A1 (en) | 2024-05-07 | 2025-11-13 | Immatics Biotechnologies Gmbh | Heteromeric proteins comprising three heteromerization improving substitution, production, combinations and applications thereof |
| CN119529098B (zh) * | 2025-01-22 | 2025-05-30 | 北京可瑞生物科技有限公司 | 对mage-a1具有特异性的结合分子和抗cd3的融合蛋白 |
Family Cites Families (105)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2018248A1 (en) | 1989-06-07 | 1990-12-07 | Clyde W. Shearman | Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| US8211422B2 (en) | 1992-03-18 | 2012-07-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric receptor genes and cells transformed therewith |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| DK1231268T3 (da) | 1994-01-31 | 2005-11-21 | Univ Boston | Polyklonale antistofbiblioteker |
| EP0979281B1 (en) | 1997-05-02 | 2005-07-20 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| AU2001270609A1 (en) | 2000-06-30 | 2002-01-14 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Heterodimeric fusion proteins |
| ES2405551T3 (es) | 2001-10-01 | 2013-05-31 | Dyax Corporation | Vectores de presentación eucariotas multicatenarios y usos de los mismos |
| US7569664B2 (en) | 2002-10-09 | 2009-08-04 | Immunocore Limited | Single chain recombinant T cell receptors |
| US8378074B2 (en) | 2005-04-01 | 2013-02-19 | Immunocore Limited | High affinity HIV T cell receptors |
| AU2006236439B2 (en) | 2005-04-15 | 2012-05-03 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| US9284375B2 (en) | 2005-04-15 | 2016-03-15 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| PL2002003T3 (pl) | 2005-05-27 | 2016-06-30 | Ospedale San Raffaele Srl | Wektor genetyczny zawierający mi-RNA |
| AT503861B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von t-zell-rezeptoren |
| WO2008045437A2 (en) | 2006-10-09 | 2008-04-17 | The General Hospital Corporation | Chimeric t-cell receptors and t-cells targeting egfrviii on tumors |
| US20110045007A1 (en) | 2007-05-31 | 2011-02-24 | Genmab A/S | Fusion or linked proteins with extended half life |
| WO2009087230A1 (en) | 2008-01-11 | 2009-07-16 | Morphosys Ag | Display vectors and methods and uses thereof |
| EP2258719A1 (en) | 2009-05-19 | 2010-12-08 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Multiple target T cell receptor |
| EP2483301A1 (en) | 2009-10-01 | 2012-08-08 | The United States Of America, As Represented By The Secretary, Department of Health and Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
| US10464987B2 (en) | 2009-10-06 | 2019-11-05 | Abbvie Inc. | Human single-chain T cell receptors |
| US20130129723A1 (en) | 2009-12-29 | 2013-05-23 | Emergent Product Development Seattle, Llc | Heterodimer Binding Proteins and Uses Thereof |
| EP2519544A1 (en) | 2009-12-29 | 2012-11-07 | Emergent Product Development Seattle, LLC | Polypeptide heterodimers and uses thereof |
| US20120294857A1 (en) | 2010-01-11 | 2012-11-22 | Trustees Of Dartmouth College | Monomeric Bi-Specific Fusion Protein |
| GB201004551D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| LT2647707T (lt) | 2010-11-30 | 2018-11-12 | Chugai Seiyaku Kabushiki Kaisha | Citotoksiškumą indukuojantis terapinis agentas |
| CA2826942C (en) | 2011-02-11 | 2021-08-03 | Memorial Sloan-Kettering Cancer Center | Hla-restricted, peptide-specific antigen binding proteins |
| WO2013026837A1 (en) | 2011-08-23 | 2013-02-28 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| UY34317A (es) | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
| BR112015011111A2 (pt) | 2012-11-30 | 2017-11-14 | Roche Glycart Ag | proteína multifuncional e formulação farmacêutica |
| EA201891502A1 (ru) | 2013-02-26 | 2018-12-28 | Роше Гликарт Аг | Биспецифические антигенсвязывающие молекулы, активирующие т-клетки |
| WO2014131711A1 (en) | 2013-02-26 | 2014-09-04 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| ES2882183T3 (es) * | 2013-03-14 | 2021-12-01 | Univ Duke | Moléculas biespecíficas que son inmunorreactivas con células efectoras inmunitarias que expresan un receptor activador |
| MX376384B (es) | 2013-11-27 | 2025-03-07 | Zymeworks Bc Inc | Construcciones de union a antigenos biespecificas dirigidas a her2. |
| KR102357961B1 (ko) | 2013-12-17 | 2022-02-08 | 제넨테크, 인크. | 항-cd3 항체 및 이의 사용 방법 |
| MX373361B (es) | 2014-03-25 | 2020-05-25 | Boehringer Ingelheim Animal Health Usa Inc | Composiciones inmunológicas que contienen histophilus somni atenuado. |
| SG10201900455YA (en) | 2014-07-24 | 2019-02-27 | Bluebird Bio Inc | Bcma chimeric antigen receptors |
| JP6919118B2 (ja) | 2014-08-14 | 2021-08-18 | ノバルティス アーゲー | ＧＦＲα−４キメラ抗原受容体を用いる癌の治療 |
| EP2985294A1 (en) | 2014-08-14 | 2016-02-17 | Deutsches Krebsforschungszentrum | Recombinant antibody molecule and its use for target cell restricted T cell activation |
| CN107074955B (zh) * | 2014-11-20 | 2021-06-22 | 豪夫迈·罗氏有限公司 | 针对FolR1和CD3的T细胞活化性双特异性抗原结合分子 |
| GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
| GB201423361D0 (en) | 2014-12-30 | 2015-02-11 | Immatics Biotechnologies Gmbh | Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides |
| GB201504502D0 (en) | 2015-03-17 | 2015-04-29 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers |
| WO2016154585A1 (en) | 2015-03-26 | 2016-09-29 | Charles Sentman | Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using |
| GB201505305D0 (en) | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| GB201505585D0 (en) | 2015-03-31 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers |
| GB201507030D0 (en) | 2015-04-24 | 2015-06-10 | Immatics Biotechnologies Gmbh | Immunotherapy against lung cancers, in particular NSCLC |
| GB201507719D0 (en) | 2015-05-06 | 2015-06-17 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers |
| KR20180029201A (ko) | 2015-05-18 | 2018-03-20 | 티씨알2 테라퓨틱스 인크. | 융합 단백질을 이용하는 tcr 리프로그래밍을 위한 조성물 및 방법 |
| EP3095792A1 (en) * | 2015-05-19 | 2016-11-23 | Klinikum rechts der Isar der Technischen Universität München | T cell receptor with specificity for myeloperoxidase peptide and uses thereof |
| GB201510771D0 (en) | 2015-06-19 | 2015-08-05 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer |
| GB201511191D0 (en) | 2015-06-25 | 2015-08-12 | Immatics Biotechnologies Gmbh | T-cell epitopes for the immunotherapy of myeloma |
| GB201511546D0 (en) | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| GB201511792D0 (en) | 2015-07-06 | 2015-08-19 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers |
| GB201512369D0 (en) | 2015-07-15 | 2015-08-19 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers |
| GB201513921D0 (en) | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| US10130693B2 (en) | 2015-08-28 | 2018-11-20 | Immatics Biotechnologies Gmbh | Peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
| GB201515321D0 (en) | 2015-08-28 | 2015-10-14 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
| GB201517538D0 (en) | 2015-10-05 | 2015-11-18 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
| WO2017059900A1 (en) | 2015-10-07 | 2017-04-13 | Biontech Cell & Gene Therapies Gmbh | Antigen receptors and uses thereof |
| MA45004A (fr) | 2015-10-09 | 2019-03-27 | Immatics Biotechnologies Gmbh | Anticorps spécifiques anti-wt1-hla |
| AU2016342041B2 (en) | 2015-10-23 | 2021-12-02 | Eureka Therapeutics, Inc. | Antibody/T-cell receptor chimeric constructs and uses thereof |
| GB201521746D0 (en) | 2015-12-10 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers |
| GB201521894D0 (en) | 2015-12-11 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against various cancers |
| GB201522592D0 (en) * | 2015-12-22 | 2016-02-03 | Immunocore Ltd | T cell receptors |
| GB201522667D0 (en) | 2015-12-22 | 2016-02-03 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers |
| GB201602918D0 (en) | 2016-02-19 | 2016-04-06 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers |
| GB201603568D0 (en) | 2016-03-01 | 2016-04-13 | Immatics Biotechnologies Gmbh | Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer |
| GB201603987D0 (en) | 2016-03-08 | 2016-04-20 | Immatics Biotechnologies Gmbh | Uterine cancer treatments |
| EP3442576A4 (en) | 2016-04-15 | 2020-05-13 | Trustees of Dartmouth College | HIGH AFFINITY B7-H6 ANTIBODIES AND ANTIBODY FRAGMENTS |
| US11732020B2 (en) | 2016-06-17 | 2023-08-22 | Medigene Immunotherapies Gmbh | T cell receptors and uses thereof |
| BR112018076555A2 (pt) | 2016-06-27 | 2019-04-02 | Procter & Gamble | aparelho e método para avaliar o tratamento de sensibilidade dentária por produto para tratamento bucal |
| WO2018026953A1 (en) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| EP3494984A4 (en) | 2016-08-05 | 2020-07-22 | Tohoku University | TREATMENT AND DIAGNOSIS OF CANCER OR INFECTIOUS DISEASES USING THE T-CELL RECEPTOR RECOGNITION MECHANISM |
| EP3512875A2 (en) | 2016-09-15 | 2019-07-24 | Quadrucept Bio Limited | Multimers, tetramers&octamers |
| CN106831996B (zh) * | 2017-03-31 | 2020-05-19 | 北京智仁美博生物科技有限公司 | 具有cd3e和/或her2靶向功能的双特异性抗体及其用途 |
| CA3064660A1 (en) | 2017-06-01 | 2018-12-06 | Universitat Stuttgart | Heterodimerizing ig domains |
| ES2871146T3 (es) | 2017-07-14 | 2021-10-28 | Immatics Biotechnologies Gmbh | Molécula de polipéptido con especificidad dual mejorada |
| WO2019047932A1 (zh) | 2017-09-08 | 2019-03-14 | 科济生物医药（上海）有限公司 | 基因工程化的t细胞及应用 |
| US20210041435A1 (en) | 2018-01-31 | 2021-02-11 | Tohoku University | Method for regulating antigen-specific mhc expression |
| BR112020023195A2 (pt) | 2018-05-14 | 2021-09-28 | Immunocore Limited | Polipeptídeos de ligação bifuncional, composição farmacêutica, ácido nucleico, vetor de expressão, célula hospedeira, método para preparar o polipeptídeo de ligação bifuncional, e método para tratar um distúrbio autoimune |
| EA202091977A1 (ru) | 2018-05-28 | 2021-02-09 | Драгонфлай Терапьютикс, Инк. | Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения |
| WO2020018715A1 (en) | 2018-07-17 | 2020-01-23 | Massachusetts Institute Of Technology | Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof |
| WO2020057610A1 (en) | 2018-09-20 | 2020-03-26 | Wuxi Biologics (Shanghai) Co., Ltd. | Novel bispecific anti-ctla-4/pd-1 polypeptide complexes |
| GB201903767D0 (en) | 2019-03-19 | 2019-05-01 | Quadrucept Bio Ltd | Multimers, tetramers & octamers |
| GB201906685D0 (en) | 2019-05-13 | 2019-06-26 | Ultrahuman Six Ltd | Activatable protein constructs and uses thereof |
| AU2020315325A1 (en) | 2019-07-15 | 2022-02-17 | Neogene Therapeutics B.V. | Method to isolate TCR genes |
| DE102019121007A1 (de) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
| US20210032370A1 (en) * | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| US20220306720A1 (en) | 2019-09-06 | 2022-09-29 | Eli Lilly And Company | Proteins comprising t-cell receptor constant domains |
| CN115066274A (zh) | 2019-09-25 | 2022-09-16 | 斯图加特大学 | 三价结合分子 |
| WO2021062382A1 (en) | 2019-09-27 | 2021-04-01 | Agenus Inc. | Heterodimeric proteins |
| AU2020384374A1 (en) | 2019-11-15 | 2022-06-09 | Seattle Project Corp. | Antigen-binding proteins targeting shared neoantigens |
| AU2020385604A1 (en) | 2019-11-18 | 2022-06-30 | BioNTech SE | Prame TCR receptors and uses thereof |
| EP4077370A4 (en) | 2019-12-17 | 2024-02-28 | The Johns Hopkins University | MANA BODY TARGETING TUMOR ANTIGENS AND METHODS OF USE |
| CN110964122B (zh) | 2019-12-24 | 2022-04-15 | 南京北恒生物科技有限公司 | T细胞受体融合蛋白及其用途 |
| IL296411A (en) | 2020-03-16 | 2022-11-01 | Univ Southern California | Novel antigen binding domains and synthetic antigen receptors incorporating them |
| WO2021188601A1 (en) | 2020-03-16 | 2021-09-23 | University Of Southern California | Methods to prevent, ameliorate and treat complications from viral infections |
| WO2021222576A1 (en) | 2020-05-01 | 2021-11-04 | A2 Biotherapeutics, Inc. | Pag1 fusion proteins and methods of making and using same |
| AU2021289612A1 (en) | 2020-06-10 | 2023-01-19 | The University Of Melbourne | HIV-1 antibodies |
| EP4188416A4 (en) | 2020-07-27 | 2024-08-21 | Arizona Board of Regents on behalf of the University of Arizona | MULTIFUNCTIONAL IMMUNOGLOBULIN-FOLDED POLYPEPTIDES FROM SUBSTITUTION TRANSLATIONAL INITIATION AND TERMINATION |
| WO2022076788A1 (en) | 2020-10-09 | 2022-04-14 | Memorial Sloan Kettering Cancer Center | Compositions targeting ndc80/mhc complexes and uses thereof |
| WO2022083668A1 (en) | 2020-10-21 | 2022-04-28 | Nanjing Legend Biotech Co., Ltd. | Use of a chimeric co-stimulatory receptor for cell therapy |
| CA3167637A1 (en) | 2020-12-21 | 2022-06-30 | Eric Escobar-Cabrera | Stabilized tcr constructs and methods of use |
| CA3208717A1 (en) | 2021-02-19 | 2022-08-25 | Preet M. Chaudhary | Single-chain and multi-chain synthetic antigen receptors for diverse immune cells |
-
2018
- 2018-07-13 ES ES18740829T patent/ES2871146T3/es active Active
- 2018-07-13 BR BR112020000762-5A patent/BR112020000762A2/pt unknown
- 2018-07-13 PE PE2020000058A patent/PE20200615A1/es unknown
- 2018-07-13 MA MA46299A patent/MA46299B1/fr unknown
- 2018-07-13 AU AU2018298884A patent/AU2018298884A1/en not_active Abandoned
- 2018-07-13 CR CR20200014A patent/CR20200014A/es unknown
- 2018-07-13 KR KR1020207004221A patent/KR20200026995A/ko not_active Ceased
- 2018-07-13 SI SI201830285T patent/SI3652215T1/sl unknown
- 2018-07-13 DK DK18183508.3T patent/DK3428194T3/da active
- 2018-07-13 HR HRP20211744TT patent/HRP20211744T1/hr unknown
- 2018-07-13 US US16/035,412 patent/US20190016802A1/en not_active Abandoned
- 2018-07-13 AU AU2018298881A patent/AU2018298881B2/en active Active
- 2018-07-13 CN CN201880046721.2A patent/CN110914307A/zh active Pending
- 2018-07-13 EP EP21191794.3A patent/EP3985029A1/en active Pending
- 2018-07-13 PT PT181835083T patent/PT3428194T/pt unknown
- 2018-07-13 PL PL18740829T patent/PL3652215T3/pl unknown
- 2018-07-13 PL PL18183508T patent/PL3428194T3/pl unknown
- 2018-07-13 MD MDE20190844T patent/MD3428194T2/ro unknown
- 2018-07-13 SI SI201830456T patent/SI3428194T1/sl unknown
- 2018-07-13 SG SG11202000025SA patent/SG11202000025SA/en unknown
- 2018-07-13 HU HUE18183508A patent/HUE057110T2/hu unknown
- 2018-07-13 CA CA3069610A patent/CA3069610A1/en active Pending
- 2018-07-13 LT LTEP18183508.3T patent/LT3428194T/lt unknown
- 2018-07-13 MD MDE20200533T patent/MD3652215T2/ro unknown
- 2018-07-13 EP EP18740829.9A patent/EP3652215B1/en active Active
- 2018-07-13 LT LTEP18740829.9T patent/LT3652215T/lt unknown
- 2018-07-13 WO PCT/EP2018/069157 patent/WO2019012141A1/en not_active Ceased
- 2018-07-13 JP JP2020501174A patent/JP2020530762A/ja active Pending
- 2018-07-13 BR BR112020000769-2A patent/BR112020000769A2/pt not_active Application Discontinuation
- 2018-07-13 US US16/035,429 patent/US20190016804A1/en not_active Abandoned
- 2018-07-13 US US16/035,420 patent/US20190016803A1/en not_active Abandoned
- 2018-07-13 ES ES18183508T patent/ES2898210T3/es active Active
- 2018-07-13 SG SG11202000027WA patent/SG11202000027WA/en unknown
- 2018-07-13 CA CA3069842A patent/CA3069842A1/en active Pending
- 2018-07-13 RS RS20211381A patent/RS62544B1/sr unknown
- 2018-07-13 DK DK18740829.9T patent/DK3652215T3/da active
- 2018-07-13 CR CR20200013A patent/CR20200013A/es unknown
- 2018-07-13 EP EP18183508.3A patent/EP3428194B1/en active Active
- 2018-07-13 PT PT187408299T patent/PT3652215T/pt unknown
- 2018-07-13 CN CN201880046726.5A patent/CN110914308A/zh active Pending
- 2018-07-13 HU HUE18740829A patent/HUE054568T2/hu unknown
- 2018-07-13 US US16/035,403 patent/US11905328B2/en active Active
- 2018-07-13 PE PE2020000056A patent/PE20200614A1/es unknown
- 2018-07-13 KR KR1020207004219A patent/KR102833184B1/ko active Active
- 2018-07-13 RS RS20210561A patent/RS61817B1/sr unknown
- 2018-07-13 WO PCT/EP2018/069151 patent/WO2019012138A1/en not_active Ceased
- 2018-07-16 TW TW107124492A patent/TWI762677B/zh not_active IP Right Cessation
- 2018-07-16 TW TW110149543A patent/TWI817302B/zh not_active IP Right Cessation
- 2018-07-17 JP JP2018134424A patent/JP6784724B2/ja active Active
-
2020
- 2020-01-14 MX MX2020011744A patent/MX2020011744A/es unknown
- 2020-01-28 CO CONC2020/0001029A patent/CO2020001029A2/es unknown
- 2020-02-10 ZA ZA2020/00842A patent/ZA202000842B/en unknown
- 2020-02-11 CO CONC2020/0001491A patent/CO2020001491A2/es unknown
-
2021
- 2021-05-06 CY CY20211100387T patent/CY1124091T1/el unknown
- 2021-11-01 CY CY20211100934T patent/CY1124835T1/el unknown
-
2022
- 2022-03-03 US US17/686,358 patent/US20220185888A1/en not_active Abandoned
- 2022-03-12 US US17/693,323 patent/US20220195044A1/en not_active Abandoned
-
2023
- 2023-05-22 JP JP2023083663A patent/JP2023103451A/ja active Pending
- 2023-06-08 US US18/331,556 patent/US20230348598A1/en active Pending
- 2023-11-24 JP JP2023198791A patent/JP2024023385A/ja active Pending
-
2025
- 2025-06-17 US US19/240,392 patent/US20250361300A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020530762A5 (enExample) | ||
| HRP20211744T1 (hr) | Poboljšana molekula polipeptida dvostruke specifičnosti | |
| JP2019023184A5 (enExample) | ||
| US20230183344A1 (en) | T-cell bispecific binding proteins | |
| EP2985294A1 (en) | Recombinant antibody molecule and its use for target cell restricted T cell activation | |
| JP2019525771A5 (enExample) | ||
| CA2321199A1 (en) | Compositions and methods for regulating lymphocyte activation | |
| JP2020529410A5 (enExample) | ||
| JPWO2021239812A5 (enExample) | ||
| JPWO2020228825A5 (enExample) | ||
| JPWO2020228824A5 (enExample) | ||
| KR20220030934A (ko) | 항-gal9 면역-억제 결합 분자 | |
| JP2021019626A5 (enExample) | ||
| HRP20210759T1 (hr) | Poboljšana molekula polipeptida dvostruke specifičnosti | |
| JP2025011201A5 (enExample) | ||
| JPWO2020087065A5 (enExample) | ||
| JPWO2021224261A5 (enExample) | ||
| TH2001000191A (th) | โมเลกุลโพลีเปปไทด์ความจำเพาะคู่ที่ปรับปรุง | |
| JPWO2022233956A5 (enExample) | ||
| US20250354995A1 (en) | Mammalian display platform for multispecific antigen binding proteins | |
| JPWO2020006568A5 (enExample) | ||
| JPWO2023110918A5 (enExample) | ||
| HK40029654B (en) | Improved dual specificity polypeptide molecule | |
| AU1872802A (en) | Compositions and methods for regulating lymphocyte activation |